NCT03274752View on ClinicalTrials.gov

Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 26, 2017

Primary Completion Date

January 1, 2021

Study Completion Date

March 1, 2022

Conditions
Cardiac RemodelingMyocardial Infarction
Interventions
DRUG

Paroxetine

Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.

DRUG

Placebo oral capsule

Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.

Trial Locations (1)

3010

Bern University Hospital, Department of Cardiology, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03274752 - Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter